Cheaib Joseph G, Hammadeh Zeyad, Su Zhuo T, Lee Seoho, Jing Yuezhou, Trock Bruce J, Han Misop
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
Urology. 2025 Jul;201:38-44. doi: 10.1016/j.urology.2025.03.051. Epub 2025 Apr 3.
To characterize trends in industry-sponsored research payments (ISRPs) to urologists in the United States METHODS: The Open Payments database was used to identify ISRPs to urologists between 2015 and 2023. Payments were stratified by recipient type and gender and analyzed by manufacturer and by associated product. Trends in total and per-urologist payment values were evaluated using standard linear and generalized linear regression models, respectively.
ISRPs to urologists increased 229% from $29.5 million in 2015 to $96.9 million in 2023 (P <.001). Payments to non-covered entities (NCEs) with a urologist principal investigator constituted most payments across all years; these increased 213% from $26.3 million in 2015 to $82.4 million in 2023 (P <.001). The median payment value to a urologist via an NCE increased 75% from $20,063 in 2015 to $35,053 in 2023 (P <.001). This trend was seen primarily among male urologists, for whom total payments increased 217% from $25.5 million in 2015 to $80.9 million in 2023 (P <.001) and median payment value per urologist increased 68% from $20,426 in 2015 to $34,255 in 2023 (P <.001); no significant change in payments was noted for female urologists within NCEs. The manufacturer and product with the highest associated total ISRP amounts during 2015-2023 were Pfizer ($196.2 million) and enzalutamide ($162.4 million), respectively.
Most ISRPs were directed to principal investigators within NCEs and increased significantly from 2015-2023. This increase was disproportionate among male and female urologists. Further research regarding potential influencing factors and detailed allocations of these research payments is warranted to improve financial transparency.
描述美国行业赞助的研究支付（ISRPs）给泌尿科医生的趋势。
使用开放支付数据库来识别2015年至2023年间给泌尿科医生的ISRPs。支付按接受者类型和性别分层，并按制造商和相关产品进行分析。分别使用标准线性回归模型和广义线性回归模型评估总支付值和每位泌尿科医生的支付值趋势。
给泌尿科医生的ISRPs从2015年的2950万美元增加到2023年的9690万美元，增长了229%（P <.001）。给以泌尿科医生为主研人员的非覆盖实体（NCEs）的支付在所有年份中占大部分；这些支付从2015年的2630万美元增加到2023年的8240万美元，增长了213%（P <.001）。通过NCE给泌尿科医生的支付中位数从2015年的20063美元增加到2023年的35053美元，增长了75%（P <.001）。这种趋势主要在男性泌尿科医生中出现，他们的总支付从2015年的2550万美元增加到2023年的8090万美元，增长了217%（P <.001），每位泌尿科医生的支付中位数从2015年的20426美元增加到2023年的34255美元，增长了68%（P <.001）；NCEs内女性泌尿科医生的支付没有显著变化。2015 - 2023年期间，相关ISRP总额最高的制造商和产品分别是辉瑞（1.962亿美元）和恩杂鲁胺（1.624亿美元）。
大多数ISRPs针对NCEs内的主要研究人员，且在2015 - 2023年期间显著增加。这种增长在男性和女性泌尿科医生中不成比例。有必要进一步研究这些研究支付的潜在影响因素和详细分配情况，以提高财务透明度。
